HLA-B27 and Spondyloarthropathy Development
Key Epidemiologic Data
- Approximately 25% of HLA-B27 positive individuals will develop spondyloarthropathy over their lifetime, based on the most robust long-term cohort data available 1
- Approximately 25% of HLA-B27 positive first-degree relatives developed axial spondyloarthropathy, regardless of whether their proband had radiographic sacroiliitis, whereas only 3% of HLA-B27 negative first-degree relatives developed the disease 1
Clinical Context and Predictive Value
- The American College of Rheumatology suggests that among HLA-B27 positive individuals presenting with inflammatory back pain, HLA-B27 testing is clinically useful, though the test alone is insufficient for diagnosis 2
Important Caveats
- The majority of HLA-B27 positive individuals (approximately 75%) will never develop spondyloarthropathy, which is why HLA-B27 testing is not recommended as a standalone screening tool in the general population 1, 2
- HLA-B27 carriage does not adversely impact survival in individuals who do not develop spondyloarthropathy, providing reassurance to those who test positive during diagnostic evaluation but remain disease-free 1
Predictive Features Beyond HLA-B27
- Acute anterior uveitis significantly increases the likelihood of developing axial spondyloarthropathy in HLA-B27 positive individuals (odds ratio: 4.7, 95% CI: 2.2-10.5) 1
- Chronic inflammatory back pain at a young age was not a reliable predictor of long-term disease development in HLA-B27 positive individuals 1
Reliability of HLA‑B27 Testing in Inflammatory Bowel Disease‑Associated Ankylosing Spondylitis
Prevalence and Predictive Value
- In patients with inflammatory bowel disease–associated ankylosing spondylitis, HLA‑B27 is present in approximately 25 %–75 % of cases, indicating that the marker is considerably less reliable for disease identification in this subgroup than in the broader axial spondyloarthropathy population. 3